ATE404211T1 - Xenon als nmda-antogonist zur neuroprotektion - Google Patents

Xenon als nmda-antogonist zur neuroprotektion

Info

Publication number
ATE404211T1
ATE404211T1 AT00948171T AT00948171T ATE404211T1 AT E404211 T1 ATE404211 T1 AT E404211T1 AT 00948171 T AT00948171 T AT 00948171T AT 00948171 T AT00948171 T AT 00948171T AT E404211 T1 ATE404211 T1 AT E404211T1
Authority
AT
Austria
Prior art keywords
xenon
nmda
antogonist
neuroprotection
modulating
Prior art date
Application number
AT00948171T
Other languages
English (en)
Inventor
Nicholas P Franks
Mervyn Maze
Original Assignee
Protexeon Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10858166&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE404211(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Protexeon Ltd filed Critical Protexeon Ltd
Application granted granted Critical
Publication of ATE404211T1 publication Critical patent/ATE404211T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT00948171T 1999-07-29 2000-07-28 Xenon als nmda-antogonist zur neuroprotektion ATE404211T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9917822.0A GB9917822D0 (en) 1999-07-29 1999-07-29 Nmda antagonist

Publications (1)

Publication Number Publication Date
ATE404211T1 true ATE404211T1 (de) 2008-08-15

Family

ID=10858166

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00948171T ATE404211T1 (de) 1999-07-29 2000-07-28 Xenon als nmda-antogonist zur neuroprotektion

Country Status (13)

Country Link
US (1) US6274633B1 (de)
EP (1) EP1200103B1 (de)
JP (1) JP5088997B2 (de)
AT (1) ATE404211T1 (de)
AU (1) AU778097B2 (de)
CA (1) CA2280310C (de)
DE (1) DE60039878D1 (de)
ES (1) ES2311466T3 (de)
GB (1) GB9917822D0 (de)
PT (1) PT1200103E (de)
RU (1) RU2257902C2 (de)
WO (1) WO2001008692A1 (de)
ZA (1) ZA200200539B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19910986C2 (de) * 1999-03-11 2001-06-07 Aga Ab Verwendung von Xenon bei der Behandlung von Neurointoxikationen
GB9913677D0 (en) * 1999-06-11 1999-08-11 Imperial College Formulation
AU2002250256B2 (en) * 2001-03-08 2008-04-03 Emory University pH-dependent NMDA receptor antagonists
GB0209998D0 (en) * 2002-05-01 2002-06-12 Protexeon Ltd Use
GB0210021D0 (en) * 2002-05-01 2002-06-12 Air Prod & Chem Ultrasonic gas analyser
GB0218153D0 (en) * 2002-08-05 2002-09-11 Ic Innovations Ltd An analgesic agent for newborn or retal subjects
US7337776B2 (en) * 2002-08-20 2008-03-04 Aga Ab Methods for easing pain and anxiety from atrial or ventricular defibrillation
US7681572B2 (en) * 2002-08-20 2010-03-23 Aga Ab Method and devices for administration of therapeutic gases
FR2858233B1 (fr) * 2003-07-30 2008-04-11 Air Liquide Sante Int Medicament gazeux inhalable a base de xenon et de protoxyde d'azote
BRPI0415232A (pt) * 2003-10-10 2006-12-12 Protexeon Ltd uso de xenÈnio com hipotermia para tratar asfixia neonatal
JP2007509091A (ja) * 2003-10-21 2007-04-12 エイジーエイ、アクティエボラーグ プログラム細胞死の防止のためのキセノンの使用
FR2863169B1 (fr) * 2003-12-08 2006-02-10 Air Liquide Sante Int Medicament gazeux inhalable a base d'argon pour le traitement des neuro-intoxications
GB0520176D0 (en) * 2005-10-04 2005-11-09 Imp College Innovations Ltd Use
EP1980261A1 (de) 2007-04-10 2008-10-15 Nicholas Peter Franks Verwendung von Helium mit Sauerstoff zur Bereitstellung von Neuroprotektion
EP1980260A1 (de) 2007-04-10 2008-10-15 Nicholas Peter Franks Verwendung hyperbarischer Bedingungen zur Bereitstellung von Neuroprotektion
CA2685446A1 (en) * 2007-04-30 2008-11-06 Nnoxe Pharmaceutiques Inc. Pharmaceutical composition comprising at least one thrombolytic agent (a) and at least one gas (b) selected from the group consisting of nitrous oxide, argon, xenon, helium, neon
CN103497114A (zh) * 2007-06-29 2014-01-08 埃莫里大学 用于神经保护的nmda受体拮抗剂
FR2952305B1 (fr) * 2009-11-10 2012-04-27 Air Liquide Medicament inhalable a base de xenon pour traiter ou pour prevenir les dyskinesies
CN103565745A (zh) 2012-08-10 2014-02-12 德克萨斯州大学系统董事会 用于治疗中风的神经保护性脂质体组合物和方法
AU2014233018A1 (en) 2013-03-15 2015-10-01 The Board Of Regents Of The University Of Texas System Liquids rich in noble gas and methods of their preparation and use
FR3022456B1 (fr) * 2014-06-20 2016-07-15 Air Liquide Xenon associe a un antagoniste des recepteurs nmda pour lutter contre une proliferation tumorale dans le systeme nerveux central

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5124319A (en) * 1991-10-11 1992-06-23 American Home Products Corporation Benzimidazole phosphono-amino acids
WO1997003677A1 (en) * 1995-07-24 1997-02-06 Trustees Of Boston University Inhibition of nmda receptor activity by pregnenolone sulfate derivatives
DE19709704C2 (de) * 1997-03-10 1999-11-04 Michael Georgieff Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie
GB9706294D0 (en) * 1997-03-26 1997-05-14 Glaxo Wellcome Spa Heterocyclic compound
DE69809827D1 (de) * 1997-03-31 2003-01-16 Korea Res Inst Chem Tech Chinolinische Sulfid-Derivate als NMDA Rezeptor-Antagonisten und Verfahren zu ihrer Herstellung
JPH1171271A (ja) * 1997-06-27 1999-03-16 Shionogi & Co Ltd グルコン酸又はその類縁体を含有するｎｍｄａ受容体拮抗剤
DE19910986C2 (de) * 1999-03-11 2001-06-07 Aga Ab Verwendung von Xenon bei der Behandlung von Neurointoxikationen

Also Published As

Publication number Publication date
EP1200103A1 (de) 2002-05-02
RU2257902C2 (ru) 2005-08-10
GB9917822D0 (en) 1999-09-29
DE60039878D1 (de) 2008-09-25
CA2280310C (en) 2008-10-14
AU6173500A (en) 2001-02-19
ES2311466T3 (es) 2009-02-16
JP2003505512A (ja) 2003-02-12
WO2001008692A1 (en) 2001-02-08
JP5088997B2 (ja) 2012-12-05
CA2280310A1 (en) 2001-01-29
PT1200103E (pt) 2008-09-17
US6274633B1 (en) 2001-08-14
EP1200103B1 (de) 2008-08-13
AU778097B2 (en) 2004-11-18
ZA200200539B (en) 2002-09-25

Similar Documents

Publication Publication Date Title
ATE404211T1 (de) Xenon als nmda-antogonist zur neuroprotektion
MXPA04009163A (es) Nuevos compuestos.
BRPI0108977B8 (pt) compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo
YU71901A (sh) NOVE VRSTE LEKOVITIH KOMPOZICIJA NA BAZI JEDINJENJA KOJA DELUJU ANTIHOLINERGIJSKI I beta-MIMETIKA
SE9503924D0 (sv) Novel opioid peptides
DE602005001445D1 (de) N-terminal monopegylierte menschliche wachstumshormon-konjugate, verfahren zu ihrer herstellung und ihre anwendung
NZ516347A (en) Indanyl-substituted benzenecarboxamides, process for their preparation, their use as a medicament and pharmaceutical formulations containing them
DK1063995T3 (da) Kombination til behandling af alkoholafhængighed indeholdende en opiod-antagonist og en NMDA-receptorkompleks-modulator
TW200606164A (en) New compounds
SE0100569D0 (sv) New compounds
MXPA01008993A (es) Tratamiento de combinacion para depresion y ansiedad.
EP1213031A3 (de) Kombinationstherapie zur Behandlung von Depression, Angstzuständen und Psychosen, die ein antidepressives und/oder anxiolytisches Mittel und einen D4-Rezeptor-Hemmer enthält
ATE400563T1 (de) Neue neurokinin-antagonisten zum gebrauch als arzneimittel
BR0013313A (pt) Derivados substituìdos de pirrolidino-2,3,4- triona-3-oxina eficazes como antagonistas de receptores de nmda
DK1237562T3 (da) Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme
DE60114597D1 (de) Naphthamid-neurokinin antagonisten zur verwendung als medikamente
MY141756A (en) Use of phenoxyacetic acid derivatives for treating hyperactive bladder
AU2001274138A1 (en) Propanolaminotetralines, preparation thereof and compositions containing same
YU59102A (sh) JEDINJENJA KORISNA ZA LEČENJE ILI PREVENCIJU OBOLJENJA U KOJEM UČESTVUJE ALFA-2β-ADRENOCEPTOR
DE50212538D1 (de) Substituierte 5,6,6a,11b-tetrahydro-7-oxa-5-aza-benzoäcüfluoren-6-carbonsäurederivate als nmda-antagonisten
MX2007002532A (es) Metodos para el tratamiento de enfermedades proliferativas de la piel utilizando derivados de carbazol.
DE69824410D1 (en) Antithrombosemittel
MXPA03005585A (es) Nuevas composiciones de medicamentos a base de anticolinergicos y agonistas de dopamina.
DE60034366D1 (de) Verfahren zur herstellung pharmazeutischer formulierungen
MXPA04005265A (es) Uso de derivados del acido 4-oxobutanoico para el tratamiento contra inflamacion.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties